Methods for monitoring the effectiveness of direct-acting anticoagulants in diabetic retinopathy

Abstract

Anticoagulants are the basis for the treatment of various diseases that induces the development of arterial and venous thrombosis. One such disease is diabetic retinopathy. However, no consensus has been reached regarding the best way to control the effectiveness of these drugs. Thus, active search is ongoing for specific biomarkers that reflect treatment quality. To this end, this study analyzed scientific papers that presented the results of various laboratory diagnostics aimed at examining the use of anticoagulants in the treatment of diabetic retinopathy.

PubMed and eLIBRARY.RU were searched for legible studies. The review analyzed studies that describe the main groups of anticoagulants and methods of laboratory control of their use and published in the past 30 years. Review articles, results of experimental studies, monographs, study guides, and dissertations were analyzed.

Anticoagulants are divided into direct and indirect. In modern clinical practice, direct ones are mainly used. To control their effectiveness, traditional methods for determining the coagulogram are mainly used; however, increasingly more often, the authors resort to a more detailed study of the rheological properties of the blood, such as determination of anti-X activity, platelet aggregation using inductors, and activity of clotting factors. In addition, determining their effect on the concentration of pro-inflammatory cytokines and growth factors in the blood serum and lacrimal fluid in diabetic retinopathy remains promising.

However, no consensus has been established on which research methods most accurately reflect the effect of anticoagulants on the hemostatic system and indicators of inflammatory activity in various diseases, particularly in diabetic retinopathy. Therefore, a detailed analysis of what laboratory parameters can change under the influence of these drugs is necessary.

Keywords

anticoagulants / biomarkers / hemostasis / diabetic retinopathy

References

[1] Netesin ES, Kuznetsov SM, Golub IE. Clinical-laboratory control of anticoagulant therapy. Siberian Medical Journal (Irkutsk). 2007;70(3):109–113. (In Russ).

[2] Нетесин Е.С., Кузнецов С.М., Голуб И.Е. Клинико-лабораторный контроль антикоагулянтной терапии // Сибирский медицинский журнал (Иркутск). 2007. Т. 70, № 3. С. 109–113.

[3] Mironova AI, Kropacheva ES, Dobrovolsky AB, et al. Modern possibilities and prospects in evaluating the anticoagulant effect of direct oral anticoagulants. Atherothrombosis. 2022;12(1):20–28. (In Russ). doi: 10.21518/2307-1109-2022-12-1-20-28

[4] Миронова А.И., Кропачева Е.С., Добровольский А.Б., и др. Современные возможности и перспективы в оценке антикоагулянтного эффекта прямых оральных антикоагулянтов // Атеротромбоз. 2022. Т. 12, № 1. С. 20–28. doi: 10.21518/2307-1109-2022-12-1-20-28

[5] Antovic J, Kondratieva TB. Methods to monitor the therapy oral anticoagulants: the current problems. Clinical Medicine (Russian Jornal). 2018;96(2):101–105. (In Russ). doi: 10.18821/0023-2149-2018-96-2-101-105

[6] Антович Й., Кондратьева Т.Б. Методы контроля терапии прямыми оральными антикоагулянтами: состояние проблемы // Клиническая медицина. 2018. Т. 96, № 2. С. 101–105. doi: 10.18821/0023-2149-2018-96-2-101-105

[7] Shafiq H, Rashid A, Majeed A. Effects of different warfarin doses on IL-6 and COX-2 levels. Pakistan Armed Forces Medical Journal. 2016;66(5):673–675.

[8] Shafiq H., Rashid A., Majeed A. Effects of different warfarin doses on IL-6 and COX-2 levels // Pakistan Armed Forces Medical Journal. 2016. Vol. 66, N 5. P. 673–675.

[9] Smythe MA, Priziola J, Dobesh PP, et al. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism J Thromb Thrombolysis. 2016;41(1): 165–186. doi: 10.1007/s11239-015-1315-2

[10] Smythe M.A., Priziola J., Dobesh P.P., et al. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism // J Thromb Thrombolysis. 2016. Vol. 41, N 1. P. 165–186. doi: 10.1007/s11239-015-1315-2

[11] Ostapenko TV, Klimenko NJu, Ostapenko OV, i dr. Sulodeksid v korrekcii funkcii jendotelija i pokazatelej gemostaza u pacientov s postkovidnym sindromom. Cardiovascular Therapy and Prevention. 2022;21(S2):59–60. (In Russ).

[12] Остапенко Т.В., Клименко Н.Ю., Остапенко О.В., и др. Сулодексид в коррекции функции эндотелия и показателей гемостаза у пациентов с постковидным синдромом // Кардиоваскулярная терапия и профилактика. 2022. Т. 21, № S2. С. 59–60.

[13] Wang P, Chi L, Zhang Z, et al. Heparin: an old drug for new clinical applications. Carbohydr Polym. 2022;295:119818. doi: 10.1016/j.carbpol.2022.119818

[14] Wang P., Chi L., Zhang Z., et al. Heparin: an old drug for new clinical applications // Carbohydr Polym. 2022. Vol. 295. P. 119818. doi: 10.1016/j.carbpol.2022.119818

[15] Bignamini AA, Chebil A, Gambaro G, Matuška J. Sulodexide for diabetic-induced disabilities: a systematic review and meta-analysis. Adv Ther. 2021;38(3):1483–1513. doi: 10.1007/s12325-021-01620-1

[16] Bignamini A.A., Chebil A., Gambaro G., Matuška J. Sulodexide for diabetic-induced disabilities: a systematic review and meta-analysis // Adv Ther. 2021. Vol. 38, N 3. P. 1483–1513. doi: 10.1007/s12325-021-01620-1

[17] Zlobina DS, Koroleva LYu, Kovaleva GV, Zlobin MV. Efficiency and safety of the long-term therapy with direct oral anticoagulants at thromboembolism of the pulmonary artery in real clinical practice. University Proceedings. Volga Region. Medical Sciences. 2019;(3): 5–18. (In Russ). doi: 10.21685/2072-3032-2019-3-1

[18] Злобина Д.С., Королева Л.Ю., Ковалева Г.В., Злобин М.В. Эффективность и безопасность длительной терапии прямыми оральными антикоагулянтами при тромбоэмболии легочной артерии в реальной клинической практике // Известия высших учебных заведений. Поволжский регион. Медицинские науки. 2019. № 3. С. 5–18. doi: 10.21685/2072-3032-2019-3-1

[19] Vinogradova AD, Malygin AS, Demidova MA. Anticoagulants in medical practice: literature review. Volga Medical Journal. 2020;19(4):27–31. (In Russ).

[20] Виноградова А.Д., Малыгин А.С., Демидова М.А. Антикоагулянты в клинической практике: обзор литературы // Верхневолжский медицинский журнал. 2020. Т. 19, № 4. С. 27–31.

[21] Bea F, Kreuzer J, Preusch M, et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26(12):2787–2792. doi: 10.1161/01.ATV.0000246797.05781.ad

[22] Bea F., Kreuzer J., Preusch M., et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice // Arterioscler Thromb Vasc Biol. 2006. Vol. 26, N 12. P. 2787–2792. doi: 10.1161/01.ATV.0000246797.05781.ad

[23] Moiseev S. Direct oral anticoagulants for prevention of recurrent stroke in patients with atrial fibrillation. Klinicheskaja farmakologija i terapija. 2021;30(3):57–66. (In Russ). doi: 10.32756/0869-5490-2021-3-57-66

[24] Моисеев С.В. Прямые оральные антикоагулянты в профилактике повторного инсульта у пациентов с фибрилляцией предсердий // Клиническая фармакология и терапия. 2021. Т. 30, № 3. С. 57–66. doi: 10.32756/0869-5490-2021-3-57-66

[25] Bel’diev SN, Egorova IV, Platonov DJu. Recommendations on the use of oral anticoagulants in elderly patients: beers criteria and evidence-based medicine. Medicina. 2019;7(4):1–11. (In Russ). doi: 10.29234/2308-9113-2019-7-4-1-11

[26] Бельдиев С.Н., Егорова И.В., Платонов Д.Ю. Рекомендации по применению пероральных антикоагулянтов у пациентов пожилого возраста: критерии Бирса и доказательная медицина // Медицина. 2019. Т. 7, № 4. С. 1–11. doi: 10.29234/2308-9113-2019-7-4-1-11

[27] Vishnevskij VI, Panina JuN. Modern aspects of treatment of patients with atrial fibrillation with new oral anticoagulants. Challenges in Modern Medicine. 2020;43(1):65–72. (In Russ). doi: 10.18413/2687-0940-2020-43-1-65-72

[28] Вишневский В.И., Панина Ю.Н. Современные аспекты лечения пациентов с фибрилляцией предсердий новыми пероральными антикоагулянтами // Актуальные проблемы медицины. 2020. Т. 43, № 1. С. 65–72. doi: 10.18413/2687-0940-2020-43-1-65-72

[29] Kadoglou NP, Moustardas P, Katsimpoulas M, et al. The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice: dabigatran etexilate and atherosclerosis. Cardiovasc Drugs Ther. 2012;26(5):367–374. doi: 10.1007/s10557-012-6411-3

[30] Kadoglou N.P., Moustardas P., Katsimpoulas M., et al. The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice: dabigatran etexilate and atherosclerosis // Cardiovasc Drugs Ther. 2012. Vol. 26, N 5. P. 367–374. doi: 10.1007/s10557-012-6411-3

[31] Testa L, Bhindi R, Agostoni P, et al. The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf. 2007;6(4):397–406. doi: 10.1517/14740338.6.4.397

[32] Testa L., Bhindi R., Agostoni P., et al. The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile // Expert Opin Drug Saf. 2007. Vol. 6, N 4. P. 397–406. doi: 10.1517/14740338.6.4.397

[33] Antovic JP, Skeppholm M, Eintrei J, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol. 2013; 69(11):1875–1881. doi: 10.1007/s00228-013-1550-4

[34] Antovic J.P., Skeppholm M., Eintrei J., et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma // Eur J Clin Pharmacol. 2013. Vol. 69, N 11. P. 1875–1881. doi: 10.1007/s00228-013-1550-4

[35] Katoh H, Nozue T, Michishita I. Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation. Heart Vessels. 2017;32(9):1130–1136. doi: 10.1007/s00380-017-0962-y

[36] Katoh H., Nozue T., Michishita I. Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation // Heart Vessels. 2017. Vol. 32, N 9. P. 1130–1136. doi: 10.1007/s00380-017-0962-y

[37] Wu TC, Chan JS, Lee CY, et al. Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol. 2015; 14:81. doi: 10.1186/s12933-015-0243-y

[38] Wu T.C., Chan J.S., Lee C.Y., et al. Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice // Cardiovasc Diabetol. 2015. Vol. 14. P. 81. doi: 10.1186/s12933-015-0243-y

[39] Hara T, Fukuda D, Tanaka K, et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis. 2015; 242(2):639–646. doi: 10.1016/j.atherosclerosis.2015.03.023

[40] Hara T., Fukuda D., Tanaka K., et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice // Atherosclerosis. 2015. Vol. 242, N 2. P. 639–646. doi: 10.1016/j.atherosclerosis.2015.03.023

[41] Zhou Q, Bea F, Preusch M, et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm. 2011;2011:432080. doi: 10.1155/2011/432080

[42] Zhou Q., Bea F., Preusch M., et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban // Mediators Inflamm. 2011. Vol. 2011. P. 432080. doi: 10.1155/2011/432080

[43] Al-Aieshy F, Malmström RE, Antovic J, et al. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016;72(6):671–679. doi: 10.1007/s00228-016-2060-y

[44] Al-Aieshy F., Malmström R.E., Antovic J., et al. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation // Eur J Clin Pharmacol. 2016. Vol. 72, N 6. P. 671–679. doi: 10.1007/s00228-016-2060-y

[45] Skeppholm M, Al-Aieshy F, Berndtsson M, et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res. 2015;136(1):148–153. doi: 10.1016/j.thromres.2015.04.030

[46] Skeppholm M., Al-Aieshy F., Berndtsson M., et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation // Thromb Res. 2015. Vol. 136, N 1. P. 148–153. doi: 10.1016/j.thromres.2015.04.030

[47] Gebekova ZA, Ivanov II, Asambayeva A, et al. Thrombodynamics test in assessing the risk of thrombus formation in patients with atrial fibrillation taking direct oral anticoagulants. Rational Pharmacotherapy in Cardiology. 2022;18(5):544–552. (In Russ). doi: 10.20996/1819-6446-2022-09-07

[48] Гебекова З.А., Иванов И.И., Асамбаева А., и др. Тест «Тромбодинамика» в оценке риска тромбообразования у пациентов с фибрилляцией предсердий, получающих прямые оральные антикоагулянты // Рациональная фармакотерапия в кардиологии. 2022. Т. 18, № 5. С. 544–552. doi: 10.20996/1819-6446-2022-09-07

[49] Laine M, Lemesle G, Dabry T, et al. Bivalirudin during percutaneous coronary intervention in acute coronary syndromes. Expert Opin Pharmacother. 2019;20(3):295–304. doi: 10.1080/14656566.2018.1551361

[50] Laine M., Lemesle G., Dabry T., et al. Bivalirudin during percutaneous coronary intervention in acute coronary syndromes // Expert Opin Pharmacother. 2019. Vol. 20, N 3. P. 295–304. doi: 10.1080/14656566.2018.1551361

[51] Sun Z, Lan X, Li S, et al. Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis. Int J Hematol. 2017;106(4):476–483. doi: 10.1007/s12185-017-2271-8

[52] Sun Z., Lan X., Li S., et al. Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis // Int J Hematol. 2017. Vol. 106, N 4. P. 476–483. doi: 10.1007/s12185-017-2271-8

[53] Averkov OV. bivalirudin and percutaneous coronary interventions in patients with acute coronary syndrome: theory and practice. Russian Journal of Cardiology. 2012;17(3):102–112. (In Russ).

[54] Аверков О.В. Теоретическое обоснование и практические аспекты использования бивалирудина при чрескожных внутрикоронарных вмешательствах у больных с острым коронарным синдромом // Российский кардиологический журнал. 2012. Т. 17, № 3. С. 102–112.

[55] Kazennova JuS. Optimizacija diagnostiki i sposoby korrekcii zaderzhki razvitija ploda [dissertation]. Novosibirsk; 2006. Available from: http://www.piyavit.ru/index.php?vm=20.view.126 (In Russ).

[56] Казеннова Ю.С. Оптимизация диагностики и способы коррекции задержки развития плода : дис. … канд. мед. наук. Новосибирск, 2006. Режим доступа: http://www.piyavit.ru/index.php?vm=20.view.126

[57] Piskunova JuA. Principy girudofarmakoterapii dlja profilaktiki i lechenija sindroma poteri ploda i gestoza u beremennyh s trombofiliej [dissertation]. Moscow; 2005. Available from: https://vivaldi.nlr.ru/bd000016531/details (In Russ).

[58] Пискунова Ю.А. Принципы гирудофармакотерапии для профилактики и лечения синдрома потери плода и гестоза у беременных с тромбофилией : автореф. дисс. … канд. мед. наук. Москва, 2005. Режим доступа: https://vivaldi.nlr.ru/bd000016531/details

[59] Mihajlova EV, Chirkova LD, Balabolkin MI, Klebanova EM. Primenenie pijavita pri saharnom diabete. Diabetes Mellitus. 1999;(2):26–27. (In Russ).

[60] Михайлова Е.В., Чиркова Л.Д., Балаболкин М.И., Клебанова Е.М. Применение пиявита при сахарном диабете // Сахарный диабет. 1999. № 2. С. 26–27.

[61] Gilyazova AR, Samoilov AN. The study of the effect of the drug “piyavit” on the hemostatic system in patients with diabetic retinopathy. Kazan Medical Journal. 2011;92(4):516–519. (In Russ).

[62] Гилязова А.Р., Самойлов А.Н. Изучение влияния препарата «пиявит» на систему гемостаза у больных диабетической ретинопатией // Казанский медицинский журнал. 2011. Т. 92, № 4. С. 516–519.

[63] Cai X, Hu D, Pan C, et al. The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes. A nationwide prospective cohort study. Sci Rep. 2019;9(1):7709. doi: 10.1038/s41598-019-44169-4

[64] Cai X., Hu D., Pan C., et al. The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes. A nationwide prospective cohort study // Sci Rep. 2019. Vol. 9, N 1. P. 7709. doi: 10.1038/s41598-019-44169-4

[65] Schwartz SS, Epstein S, Corkey BE, et al. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification Schema. Diabetes Care. 2016;39(2):179–186. doi: 10.2337/dc15-1585

[66] Schwartz S.S., Epstein S., Corkey B.E., et al. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification Schema // Diabetes Care. 2016. Vol. 39, N 2. P. 179–186. doi: 10.2337/dc15-1585

[67] Ivanova NV, Jarosheva NA. Disbalans v sisteme gemostaza i jendotelial’naja disfunkcija u bol’nyh s diabeticheskoj retinopatiej. Journal of Ophthalmology. 2008;(3):33–38. (In Russ).

[68] Иванова Н.В., Ярошева Н.А. Дисбаланс в системе гемостаза и эндотелиальная дисфункция у больных с диабетической ретинопатией // Офтальмологический журнал. 2008. № 3. С. 33–38.

[69] Shelkovnikova TV, Shishljannikova NJu, Vavin GV, i dr. Izmenenija v sisteme gemostaza u pacientov s diabeticheskoj retinopatiej. Medical Alphabet. 2014;1(2):32–34. (In Russ).

[70] Шелковникова Т.В., Шишлянникова Н.Ю., Вавин Г.В., и др. Изменения в системе гемостаза у пациентов с диабетической ретинопатией // Медицинский алфавит. 2014. Т. 1, № 2. С. 32–34.

[71] Leley SP, Ciulla TA, Bhatwadekar AD. Diabetic retinopathy in the aging population: a perspective of pathogenesis and treatment. Clin Interv Aging. 2021;16:1367–1378. doi: 10.2147/CIA.S297494

[72] Leley S.P., Ciulla T.A., Bhatwadekar A.D. Diabetic retinopathy in the aging population: a perspective of pathogenesis and treatment // Clin Interv Aging. 2021. Vol. 16. P. 1367–1378. doi: 10.2147/CIA.S297494

[73] Heng LZ, Comyn O, Peto T, et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet Med. 2013;30(6):640–650. doi: 10.1111/dme.12089

[74] Heng L.Z., Comyn O., Peto T., et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments // Diabet Med. 2013. Vol. 30, N 6. P. 640–650. doi: 10.1111/dme.12089

[75] Mamedov TH, Narkevich AN. Detection of the signs of diabetic retinopathy using classification mathematical models. Journal of New Medical Technologies. 2021;28(2):107–110. (In Russ). doi: 10.24412/1609-2163-2021-2-107-110

[76] Мамедов Т.Х., Наркевич А.Н. Распознавание признаков диабетической ретинопатии с применением классификационных математических моделей // Вестник новых медицинских технологий. 2021. Т. 28, № 2. С. 107–110. doi: 10.24412/1609-2163-2021-2-107-110

[77] Nguyen TT, Wang JJ, Sharrett AR, et al. Relationship of retinal vascular caliber with diabetes and retinopathy: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2008;31(3): 544–549. doi: 10.2337/dc07-1528

[78] Nguyen T.T., Wang J.J., Sharrett A.R., et al. Relationship of retinal vascular caliber with diabetes and retinopathy: the Multi-Ethnic Study of Atherosclerosis (MESA) // Diabetes Care. 2008. Vol. 31, N 3. P. 544–549. doi: 10.2337/dc07-1528

[79] Cai S, Liu TYA. Fluorescein angiography in diagnosis and treatment of diabetic retinopathy. Curr Diab Rep. 2021;21(9):30. doi: 10.1007/s11892-021-01398-0

[80] Cai S., Liu T.Y.A. Fluorescein angiography in diagnosis and treatment of diabetic retinopathy // Curr Diab Rep. 2021. Vol. 21, N 9. P. 30. doi: 10.1007/s11892-021-01398-0

[81] Ashraf M, Sampani K, AbdelAl O, et al. Disparity of microaneurysm count between ultrawide field colour imaging and ultrawide field fluorescein angiography in eyes with diabetic retinopathy. Br J Ophthalmol. 2020;104(12):1762–1767. doi: 10.1136/bjophthalmol-2019-315807

[82] Ashraf M., Sampani K., AbdelAl O., et al. Disparity of microaneurysm count between ultrawide field colour imaging and ultrawide field fluorescein angiography in eyes with diabetic retinopathy // Br J Ophthalmol. 2020. Vol. 104, N 12. P. 1762–1767. doi: 10.1136/bjophthalmol-2019-315807

[83] Khalid H, Schwartz R, Nicholson L, et al. Widefield optical coherence tomography angiography for early detection and objective evaluation of proliferative diabetic retinopathy. Br J Ophthalmol. 2021;105(1):118–123. doi: 10.1136/bjophthalmol-2019-315365

[84] Khalid H., Schwartz R., Nicholson L., et al. Widefield optical coherence tomography angiography for early detection and objective evaluation of proliferative diabetic retinopathy // Br J Ophthalmol. 2021. Vol. 105, N 1. P. 118–123. doi: 10.1136/bjophthalmol-2019-315365

[85] Virgili G, Menchini F, Casazza G. et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:CD008081. doi: 10.1002/14651858.CD008081.pub3

[86] Virgili G., Menchini F., Casazza G., et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy // Cochrane Database Syst Rev. 2015. N 1. P. CD008081. doi: 10.1002/14651858.CD008081.pub3

[87] Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. doi: 10.1159/000458539

[88] Schmidt-Erfurth U., Garcia-Arumi J., Bandello F., et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA) // Ophthalmologica. 2017. Vol. 237, N 4. P. 185–222. doi: 10.1159/000458539

[89] Gildea D. The diagnostic value of optical coherence tomography angiography in diabetic retinopathy: a systematic review. Int Ophthalmol. 2019;39(10):2413–2433. doi: 10.1007/s10792-018-1034-8

[90] Gildea D. The diagnostic value of optical coherence tomography angiography in diabetic retinopathy: a systematic review // Int Ophthalmol. 2019. Vol. 39, N 10. P. 2413–2433. doi: 10.1007/s10792-018-1034-8

[91] Suciu CI, Suciu VI, Nicoara SD. Optical coherence tomography (angiography) biomarkers in the assessment and monitoring of diabetic macular edema. J Diabetes Res. 2020;2020:6655021. doi: 10.1155/2020/6655021

[92] Suciu C.I., Suciu V.I., Nicoara S.D. Optical coherence tomography (angiography) biomarkers in the assessment and monitoring of diabetic macular edema // J Diabetes Res. 2020. Vol. 2020. P. 6655021. doi: 10.1155/2020/6655021

[93] Yurova OV, Turova EA, Morozova NE, et al. Treatment and secondary prophylaxis integrated approach at non-proliferative diabetic retinopathy. Ophthalmology in Russia. 2011;8(3):9–12. (In Russ).

[94] Юрова О.В., Турова Е.А., Морозова Н.Е., и др. Комплексный подход при вторичной профилактике и терапии непролиферативной диабетической ретинопатии // Офтальмология. 2011. Т. 8, № 3. С. 9–12.

[95] Avetisov SJe, Egorov EA, Moshetova LK, et al, editors. Oftal’mologija. Nacional’noe rukovodstvo. Kratkoe izdanie. Moscow: GJeOTAR-Media; 2014. 736 p. (In Russ).

[96] Офтальмология. Национальное руководство. Краткое издание / под ред. С.Э. Аветисова, Е.А. Егорова, Л.К. Мошетовой, и др. Москва : ГЭОТАР-Медиа, 2014. 736 с.

[97] Filippov VM, Petrachkov DV, Budzinskaya MV, Matyushchenko AG. The role of neurodegeneration biomarkers in the management of patients with diabetic retinopathy. The Russian Annals of Ophthalmology. 2021;137(5-2):314–322. (In Russ). doi: 10.17116/oftalma2021137052314

[98] Филиппов В.М., Петрачков Д.В., Будзинская М.В., Матющенко А.Г. Роль биомаркеров нейродегенерации при диабетической ретинопатии // Вестник офтальмологии. 2021. Т. 137, № 5-2. С. 314–322. doi: 10.17116/oftalma2021137052314

[99] Jarilin AA. Immunologija. Moscow: GJeOTAR-Media; 2010. 752 p. (In Russ).

[100] Ярилин А.А. Иммунология: учебник. Москва : ГЭОТАР- Медиа», 2010. 752 с.

RIGHTS & PERMISSIONS

Eco-Vector